Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam Gandy

Showing results (31-40 of 191) with videos related to

Pageof 20
Sort By:
Neuron|May 31, 2013
Microglia as dynamic and essential components of the amyloid hypothesisSam Gandy, Frank L Heppner
The Journal of Experimental Medicine|May 14, 2021
Alzheimer mutant speeds APP transportSam Gandy, Michelle E Ehrlich
Journal of Neuroinflammation|December 1, 2023
Correction: miR155, TREM2, INPP5D: Disease stage and cell-type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer's amyloidopathySam Gandy, Michelle E Ehrlich
The Mount Sinai Journal of Medicine, New York|January 27, 2010
Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's DiseaseAlex L Lublin, Sam Gandy
Annual Review of Medicine|January 19, 2013
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progressSam Gandy, Steven T DeKosky
Nature Reviews. Urology|February 24, 2016
Prostate cancer: Increased dementia risk following androgen deprivation therapy?Ralph N Martins, Sam Gandy
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2019
Unexpected systemic phenotypes result from focal combined deficiencies of forebrain insulin receptor/IGF-1 receptor signalingSam Gandy, Derek M Huffman
JAMA Neurology|January 30, 2014
Environmental exposures and the risk for Alzheimer disease: can we identify the smoking guns?Steven T Dekosky, Sam Gandy
The Lancet. Neurology|July 22, 2005
Alzheimer's amyloid immunotherapy: quo vadis?Sam Gandy, Frank L Heppner
The Lancet. Neurology|December 15, 2012
2012: the year in dementiaSam Gandy, Steven T DeKosky
Pageof 20

Showing results (31-40 of 191) with videos related to

Sort By:
Pageof 20
Neuron|May 31, 2013
Microglia as dynamic and essential components of the amyloid hypothesisSam Gandy, Frank L Heppner
The Journal of Experimental Medicine|May 14, 2021
Alzheimer mutant speeds APP transportSam Gandy, Michelle E Ehrlich
Journal of Neuroinflammation|December 1, 2023
Correction: miR155, TREM2, INPP5D: Disease stage and cell-type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer's amyloidopathySam Gandy, Michelle E Ehrlich
The Mount Sinai Journal of Medicine, New York|January 27, 2010
Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's DiseaseAlex L Lublin, Sam Gandy
Annual Review of Medicine|January 19, 2013
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progressSam Gandy, Steven T DeKosky
Nature Reviews. Urology|February 24, 2016
Prostate cancer: Increased dementia risk following androgen deprivation therapy?Ralph N Martins, Sam Gandy
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2019
Unexpected systemic phenotypes result from focal combined deficiencies of forebrain insulin receptor/IGF-1 receptor signalingSam Gandy, Derek M Huffman
JAMA Neurology|January 30, 2014
Environmental exposures and the risk for Alzheimer disease: can we identify the smoking guns?Steven T Dekosky, Sam Gandy
The Lancet. Neurology|July 22, 2005
Alzheimer's amyloid immunotherapy: quo vadis?Sam Gandy, Frank L Heppner
The Lancet. Neurology|December 15, 2012
2012: the year in dementiaSam Gandy, Steven T DeKosky
Pageof 20